Combinostics selected to join the 2019 MassChallenge HealthTech cohort

Combinostics is a Finnish digital health company that develops and markets advanced tools for data-driven diagnostics. The technology is generic and can be applied to any disease area but Combinostics’ first application concerns early detection and differential diagnostics in Alzheimer’s disease and other dementias. Combinostics’ cNeuro® platform includes cMRI for quantification of MRI brain scans and cDSI for data-driven clinical decision support in dementia. cNeuro cMRI and cDSI have been certified according to the European Medical Device Directive (93/42/EEC). cNeuro cMRI is FDA 510(k) cleared and cDSI is excluded from the definition of a device in the US based on section 520(o)(1)(E) of the FD&C Act.